Keywords
Esophageal Neoplasms ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

40 Search results.

Eligibility Localized Squamous Cell Carcinoma of the Esophagus NCT02017600

- 7/2/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus; ODM derived from: https://clinicaltrials.gov/show/NCT02017600

Eligibility Esophageal Squamous Cell Carcinoma Resectable NCT01688700

- 12/16/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01688700

Eligibility Esophageal Squamous Cell Carcinoma NCT01822613

- 12/16/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC); ODM derived from: https://clinicaltrials.gov/show/NCT01822613

Eligibility Esophageal Squamous Cell Carcinoma NCT01402180

- 12/16/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy; ODM derived from: https://clinicaltrials.gov/show/NCT01402180

Eligibility Esophageal Squamous Cell Carcinoma NCT01391572

- 12/14/19 - 1 form, 2 itemgroups, 22 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01391572

Eligibility Esophageal Squamous Cell Carcinoma NCT01258192

- 12/14/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01258192

Eligibility Esophageal Carcinoma NCT01937208

- 12/14/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Comparable Study of Different Radiation Dose in Esophageal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01937208

Eligibility Esophageal Carcinoma NCT01034683

- 12/13/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01034683

Eligibility Esophageal Squamous Carcinoma NCT01752205

- 12/8/19 - 1 form, 2 itemgroups, 26 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01752205

Eligibility Stage IV Esophageal Squamous Cell Carcinoma NCT02034968

- 7/11/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02034968

Eligibility Stage IV Esophageal Squamous Cell Carcinoma NCT02011594

- 7/11/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02011594

Eligibility Stage III Esophageal Squamous Cell Carcinoma NCT02025036

- 7/10/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02025036